Imbruvica and Amitiza drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Imbruvica and Amitiza. Common interactions include central nervous system lymphoma among females and asthenia among males.

The phase IV clinical study analyzes what interactions people who take Imbruvica and Amitiza have. It is created by eHealthMe based on reports of 18 people who take Imbruvica and Amitiza from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 30, 2022

18 people who take Imbruvica and Amitiza together, and have interactions are studied.


What is Imbruvica?

Imbruvica has active ingredients of ibrutinib. It is often used in chronic lymphocytic leukemia (cll). eHealthMe is studying from 50,134 Imbruvica users for its effectiveness, alternative drugs and more.

What is Amitiza?

Amitiza has active ingredients of lubiprostone. It is often used in constipation. eHealthMe is studying from 9,586 Amitiza users for its effectiveness, alternative drugs and more.

Number of Imbruvica and Amitiza reports submitted per year:

Imbruvica and Amitiza drug interactions.

Common Imbruvica and Amitiza drug interactions by gender *:

female:

  1. Central nervous system lymphoma
  2. Disease progression
  3. Mycosis fungoides
  4. Death
  5. Pleural effusion
  6. Atrial fibrillation
  7. Blister
  8. Dysgeusia
  9. Epistaxis
  10. Gingival bleeding

male:

  1. Asthenia
  2. Fall
  3. Tooth disorder
  4. Tooth extraction
  5. Influenza
  6. Nasopharyngitis
  7. Postoperative adhesion
  8. Cardiac disorder
  9. Nephrolithiasis
  10. Pancreatitis

Common Imbruvica and Amitiza drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Local swelling
  2. Neck pain
  3. Pharyngeal oedema
  4. Pyrexia

60+:

  1. Central nervous system lymphoma
  2. Disease progression
  3. Mouth haemorrhage
  4. Abnormal behaviour
  5. Pancreatic carcinoma
  6. Tooth disorder
  7. Tooth extraction
  8. Influenza
  9. Nasopharyngitis
  10. Pleural effusion

Common conditions people have *:

  1. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 12 people, 66.67%
  2. Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 2 people, 11.11%
  3. T-Cell Lymphoma (a blood cell cancer): 1 person, 5.56%
  4. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 5.56%
  5. Chronic Lymphocytic Leukaemia Stage 4 (blood cell cancer with too few blood platelets), with or without anaemia, enlarged lymph nodes, spleen, or liver): 1 person, 5.56%
  6. B-Cell Small Lymphocytic Lymphoma (blood cancer affecting b cells): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Imbruvica and Amitiza?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Imbruvica and Amitiza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Imbruvica side effects:

Browse all side effects of Imbruvica:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Amitiza side effects:

Browse all side effects of Amitiza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Imbruvica interactions:

Browse all interactions between Imbruvica and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Amitiza interactions:

Browse all interactions between Amitiza and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ibrutinib and lubiprostone (the active ingredients of Imbruvica and Amitiza, respectively), and Imbruvica and Amitiza (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Imbruvica and Amitiza.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: